Strategic Partnerships ANGLE has recent collaboration activity with major pharma players (AstraZeneca contract in 2024 and a Myriad Genetics research partnership in 2025), indicating receptiveness to collaborative R&D ventures and diagnostic service expansions that can be leveraged for co-development, licensing, or joint clinical programs.

Clinical Services Growth In addition to its diagnostic systems, ANGLE operates GCP-compliant laboratories in the UK and US offering custom assay development and clinical trial testing, presenting opportunities to upsell expanded assay menus, validation studies, and contract research for CROs and biopharma.

High Impact Data ANGLE highlights extensive peer‑reviewed validation of its Parsortix system and ongoing data presentations at cancer-focused conferences, suggesting a strong evidence base to pursue larger clinical trials, real‑world studies, and reimbursement discussions that can drive broader adoption.

Global Commercial Reach With FDA clearance for Parsortix and international commercial focus, there is potential to expand into new markets or institutions seeking liquid biopsy capabilities, especially in oncology research programs, companion diagnostics, and diagnostic service outsourcing.

Technology Enablement The Parsortix PC1 harvesting platform enables downstream whole cell imaging, proteomics, and multi-omics analyses, offering sales angles for complementing clients' existing workflows with end-to-end liquid biopsy solutions, data services, and integration with cloud-based analytics.